ALGS Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Aligos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.84 |
| 52 Week High | US$41.64 |
| 52 Week Low | US$6.76 |
| Beta | 2.73 |
| 1 Month Change | 98.80% |
| 3 Month Change | 388.83% |
| 1 Year Change | 127.66% |
| 3 Year Change | -87.11% |
| 5 Year Change | n/a |
| Change since IPO | -89.27% |
Recent News & Updates
Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks
Dec 11Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth?
Nov 27
Recent updates
Aligos Therapeutics: Promising Pipeline With Cash And Dilution Risks
Dec 11Can Aligos Therapeutics (NASDAQ:ALGS) Afford To Invest In Growth?
Nov 27Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry
Jul 31Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely
Jul 16Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues
May 24Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01Shareholder Returns
| ALGS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.4% | -3.8% | -2.7% |
| 1Y | 127.7% | -2.6% | 23.4% |
Return vs Industry: ALGS exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: ALGS exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| ALGS volatility | |
|---|---|
| ALGS Average Weekly Movement | 18.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ALGS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALGS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 68 | Larry Blatt | www.aligos.com |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
Aligos Therapeutics, Inc. Fundamentals Summary
| ALGS fundamental statistics | |
|---|---|
| Market cap | US$147.87m |
| Earnings (TTM) | -US$76.95m |
| Revenue (TTM) | US$6.00m |
24.7x
P/S Ratio-1.9x
P/E RatioIs ALGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALGS income statement (TTM) | |
|---|---|
| Revenue | US$6.00m |
| Cost of Revenue | US$76.50m |
| Gross Profit | -US$70.50m |
| Other Expenses | US$6.46m |
| Earnings | -US$76.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -20.73 |
| Gross Margin | -1,175.55% |
| Net Profit Margin | -1,283.19% |
| Debt/Equity Ratio | 0% |
How did ALGS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aligos Therapeutics, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Antonio Arce | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |